Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Experimental Hepatitis C Treatment Not Effective in Monthly Dose, Trial Data Indicate

March 16, 2006

Albuferon, an experimental hepatitis C treatment from Human Genome Sciences, is not effective when administered on a monthly basis but is more effective when taken every two weeks in combination with another medication, according to trial data released by the company on Tuesday, the Wall Street Journal reports. About 75% of patients taking a 1,200-microgram dose of Albuferon every two weeks in combination with Ribavirin exhibited lower hepatitis C viral levels, compared with 66% of patients receiving 180 micrograms of Pegasys, a hepatitis C treatment from Roche Holding, every seven days, according to phase III trial data. The trial finds that Albuferon was not as effective as Pegasys when taken at four-week intervals, although it might be more effective if given in higher doses, the Journal reports (Hinton, Wall Street Journal, 3/15). According to the Washington Post, the data "raised questions about whether Albuferon is superior enough to let it compete with entrenched products that doctors are long accustomed to prescribing." Albuferon -- a variation of interferon, which has been on the market for several years -- was developed "to work better than existing forms of the drug while allowing people to inject themselves less often," the Post reports. HGS said it will move forward with larger scale trials to receive FDA approval. HGS CEO H. Thomas Watkins said, "Quite honestly, we like what we see in terms of these interim results" (Gillis, Washington Post, 3/15).

Back to other news for March 16, 2006


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2006 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More HIV News

Tools
 

Advertisement